A novel testing service to rapidly identify stroke patients not responding to Clopidogrel antithrombotic therapy, and switch them to alternative effective medication. (Platelet Solutions-RPFT).

一种新颖的测试服务，可快速识别对氯吡格雷抗血栓治疗无反应的中风患者，并将其转为替代有效药物。

• 批准号: 710746
• 金额: $ 9万
• 依托单位: PLATELET SOLUTIONS LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Concept
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=710746
• 关键词: novel; testing; service; rapidly; identify

PLATELET SOLUTIONS LTD (PS Ltd.) is a micro-SME founded on extensive research andexperience in Cardiovascular Medicine at Nottingham University. A stroke occurs whenblood flow in the brain is interrupted; either due to blood clots, ischaemic stroke (IS), or anartery bursts (haemorrhagic stroke). One occurs every 3 mins 27 s in the UK striking peopleof all ages - each year in the UK there are 90.1k ISs, and 46k transient ischaemic attacks(TIAs or mini-strokes, where symptoms resolve in 24 hrs). In 2009 the total annual costs ofstroke care were estimated at £9b - 5% of total UK NHS costs - direct care of £4.5b, informalcare £2.4b, and indirect costs of £2.1b. Within 5 years of the first stroke there is a ca. 25% riskof recurrence of a more debilitating event. To reduce the risk of another stroke all patientsafter IS and TIA receive antiplatelet treatment with clopidogrel for life. However, not allpatients respond to the drug therapy and no testing is performed to identify them placing thissub-group at higher risk of another stroke. We have developed a commercially and technologyinnovative testing service to identify patients who are not benefiting from clopidogrel drugtherapy and for whom widely available alternative therapy (aspirin with dipyridamole) wouldbe beneficial. We project that full uptake of the service could save the NHS up to £38.5m p.a.in direct medical costs, and the UK economy £79.1m p.a. in informal care and productivityloses. Success of the project will transform Platelet Solutions Ltd. to a SME.

PLATELET SOLUTIONS LTD（PS Ltd.）是一家微型中小企业，建立在诺丁汉大学心血管医学的广泛研究和经验基础上。当大脑中的血流中断时发生中风;由于血栓、缺血性中风（IS）或动脉破裂（出血性中风）。在英国，每3分钟27秒就会发生一次，袭击所有年龄段的人--英国每年有90.1k例IS和46，000例短暂性脑缺血发作（TIA或小型中风，症状在24小时内消退）。2009年，中风护理的年度总成本估计为90亿英镑-占英国国民保健服务总成本的5%-直接护理45亿英镑，非正式护理24亿英镑，间接成本21亿英镑。在第一次中风后的5年内，有一个病例。25%的风险复发的一个更衰弱的事件。为了降低再次卒中的风险，所有IS和TIA后的患者终身接受氯吡格雷抗血小板治疗。然而，并不是所有的患者对药物治疗都有反应，也没有进行任何检测来识别他们，这使得这一亚组再次中风的风险更高。我们已经开发了一种商业和技术创新的检测服务，以识别那些不能从氯吡格雷药物治疗中获益的患者，以及那些广泛使用的替代治疗（阿司匹林和双嘧达莫）将是有益的患者。我们预计，全面采用这项服务可以为NHS节省高达3850万英镑p.a.in直接医疗费用，并为英国经济每年节省7910万英镑。in informal非正式care护理and productivityyloses生产力.该项目的成功将使血小板解决方案有限公司转变为中小企业。